ATE405643T1 - Thrombinzusammensetzungen - Google Patents

Thrombinzusammensetzungen

Info

Publication number
ATE405643T1
ATE405643T1 AT05766031T AT05766031T ATE405643T1 AT E405643 T1 ATE405643 T1 AT E405643T1 AT 05766031 T AT05766031 T AT 05766031T AT 05766031 T AT05766031 T AT 05766031T AT E405643 T1 ATE405643 T1 AT E405643T1
Authority
AT
Austria
Prior art keywords
compositions
thrombine
thrombin
cacl2
mannitol
Prior art date
Application number
AT05766031T
Other languages
English (en)
Inventor
Shan Jiang
Richard Senderoff
Jeffrey Meyer
Original Assignee
Zymogenetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zymogenetics Inc filed Critical Zymogenetics Inc
Application granted granted Critical
Publication of ATE405643T1 publication Critical patent/ATE405643T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7012Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/48Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482Serine endopeptidases (3.4.21)
    • A61K38/4833Thrombin (3.4.21.5)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L24/00Surgical adhesives or cements; Adhesives for colostomy devices
    • A61L24/04Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
    • A61L24/10Polypeptides; Proteins
    • A61L24/106Fibrin; Fibrinogen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424Serine endopeptidases (3.4.21)
    • C12N9/6429Thrombin (3.4.21.5)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y304/00Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21Serine endopeptidases (3.4.21)
    • C12Y304/21005Thrombin (3.4.21.5)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
AT05766031T 2004-06-22 2005-06-21 Thrombinzusammensetzungen ATE405643T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US58182404P 2004-06-22 2004-06-22

Publications (1)

Publication Number Publication Date
ATE405643T1 true ATE405643T1 (de) 2008-09-15

Family

ID=34981715

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05766031T ATE405643T1 (de) 2004-06-22 2005-06-21 Thrombinzusammensetzungen

Country Status (11)

Country Link
US (2) US7393674B2 (de)
EP (1) EP1766003B1 (de)
JP (1) JP4767253B2 (de)
AT (1) ATE405643T1 (de)
AU (2) AU2005265251B2 (de)
CA (1) CA2570478C (de)
DE (1) DE602005009191D1 (de)
DK (1) DK1766003T3 (de)
ES (2) ES2313383T3 (de)
IL (1) IL179852A0 (de)
WO (1) WO2006009989A1 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4767253B2 (ja) * 2004-06-22 2011-09-07 ザイモジェネティクス, インコーポレイテッド トロンビン組成物
US8233963B2 (en) 2007-02-19 2012-07-31 Medtronic Navigation, Inc. Automatic identification of tracked surgical devices using an electromagnetic localization system
AU2008266094B2 (en) * 2007-06-15 2014-01-30 Baxter International Inc. Stabilized thrombin compositions
US10046081B2 (en) 2008-04-11 2018-08-14 The Henry M Jackson Foundation For The Advancement Of Military Medicine, Inc. Electrospun dextran fibers and devices formed therefrom
EP2269594B1 (de) 2008-04-16 2016-03-02 The Chemo-Sero-Therapeutic Research Institute Verfahren zur herstellung eines thrombin-immobilisierten biologisch absorbierbaren folienpräparats
EP2113564A1 (de) * 2008-05-01 2009-11-04 Arecor Limited Proteinformulierung
CA2801118C (en) 2010-06-01 2016-01-05 Baxter International Inc. Process for making dry and stable hemostatic compositions
MX352875B (es) * 2010-06-01 2017-12-13 Baxter Healthcare Sa Proceso para elaborar composiciones hemostaticas secas y estables.
US8697118B2 (en) * 2011-10-18 2014-04-15 St. Teresa Medical, Inc. Stabilizers for hemostatic products
JP6241624B2 (ja) 2012-03-06 2017-12-06 フェロサン メディカル デバイシーズ エイ/エス 止血ペーストを収容する加圧容器
CN104349797B (zh) 2012-06-12 2017-10-27 弗罗桑医疗设备公司 干止血组合物
US9149529B2 (en) 2012-10-24 2015-10-06 Orthovita, Inc. Stable compositions containing thrombin and methods for preparation and use thereof
US9212357B2 (en) * 2012-12-03 2015-12-15 Omrix Biopharmaceuticals Ltd. Thrombin solution and methods of use thereof
EP3010419B1 (de) 2013-06-21 2020-05-20 Ferrosan Medical Devices A/S Vakuumerweiterte trockenzusammensetzung und spritze zum zurückhalten davon
CN104274827B (zh) * 2013-07-01 2020-07-14 上海贺普药业股份有限公司 贺普拉肽的制剂
EP3079731B1 (de) 2013-12-11 2018-08-08 Ferrosan Medical Devices A/S Trockenzusammensetzung mit extrusionsverstärker
JP6726852B2 (ja) 2014-10-13 2020-07-22 フェッローサン メディカル ディバイス エー/エス 止血および創傷治癒に使用するための乾燥組成物
RU2705905C2 (ru) 2014-12-24 2019-11-12 Ферросан Медикал Дивайсиз А/С Шприц для удерживания и смешивания первого и второго веществ
EP3242656A4 (de) * 2015-01-06 2018-08-29 St. Teresa Medical, Inc. Hämostatika
AU2016290433B2 (en) 2015-07-03 2018-05-24 Ferrosan Medical Devices A/S Syringe for mixing two components and for retaining a vacuum in a storage condition
NZ741447A (en) 2015-11-06 2022-12-23 Ethicon Inc Compacted hemostatic cellulosic aggregates
US10828387B2 (en) 2015-11-12 2020-11-10 St. Teresa Medical, Inc. Method of sealing a durotomy
US11413335B2 (en) 2018-02-13 2022-08-16 Guangzhou Bioseal Biotech Co. Ltd Hemostatic compositions and methods of making thereof
CN107754005B (zh) * 2016-08-15 2021-06-15 广州倍绣生物技术有限公司 止血组合物及其制造方法
US10953128B2 (en) 2017-11-02 2021-03-23 St. Teresa Medical, Inc. Fibrin sealant products
CN112368028A (zh) 2018-05-09 2021-02-12 弗罗桑医疗设备公司 用于制备止血组合物的方法
IL261190A (en) * 2018-08-16 2019-01-31 Omrix Biopharmaceuticals Ltd Stable liquid preparations of thrombin
EP4243796A4 (de) 2020-11-16 2025-01-22 Orcosa Inc. Verbesserte verwendung von cannabinoiden bei der behandlung von epilepsie
US11672761B2 (en) 2020-11-16 2023-06-13 Orcosa Inc. Rapidly infusing platform and compositions for therapeutic treatment in humans
CN116531496A (zh) * 2022-01-25 2023-08-04 上海利康瑞生物工程有限公司 一种凝血酶液体冷冻制剂及其制备方法和应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4363319A (en) * 1980-06-30 1982-12-14 Applied Medical Devices, Inc. Ready-to-use bandage incorporating a coagulant composition and method of preparing same
US4696812A (en) * 1985-10-28 1987-09-29 Warner-Lambert Company Thrombin preparations
JPS63243032A (ja) * 1987-03-27 1988-10-07 Green Cross Corp:The トロンビンの加熱処理方法
JPS6440433A (en) * 1987-08-05 1989-02-10 Green Cross Corp Aqueous liquid composition of thrombin
US5281528A (en) * 1989-12-18 1994-01-25 Warner-Lambert Company Process for purified thromboplastin for ultra-pure thrombin preparation
ES2131504T3 (es) * 1990-02-20 1999-08-01 Baxter Int Trombina humana purificada viricamente segura.
JPH0813750B2 (ja) 1990-03-01 1996-02-14 持田製薬株式会社 経口用トロンビン製剤
EP0505604B1 (de) 1991-03-28 1996-09-25 Warner-Lambert Company Hochreine Thrombinzubereitung
AU1086795A (en) * 1993-11-03 1995-05-23 Clarion Pharmaceuticals, Inc. Hemostatic patch
RU2136319C1 (ru) * 1993-12-23 1999-09-10 Джонсон энд Джонсон Медикал, Инк. Биоабсорбируемое хирургическое гемостатическое средство и способ его получения (варианты)
JP2002514960A (ja) * 1997-06-18 2002-05-21 コヘージョン テクノロジーズ,インコーポレイテッド トロンビンおよびミクロフィブリルコラーゲンを含む組成物、ならびにその調製および使用の方法
US6310183B1 (en) * 1997-09-10 2001-10-30 Novo Nordisk A/S Coagulation factor VIIa composition
US5981254A (en) * 1997-10-30 1999-11-09 Haemacure Corporation Process for producing thrombin from plasma
AU7320300A (en) 1999-09-27 2001-04-30 International Reagents Corporation Means of stabilizing thrombin and compositions
US6399385B1 (en) * 1999-09-29 2002-06-04 The Trustees Of The University Of Pennsylvania Methods for rapid PEG-modification of viral vectors, compositions for enhanced gene transduction, compositions with enhanced physical stability, and uses therefor
US20050232899A1 (en) * 2002-05-31 2005-10-20 Aradigm Corporation Compositions methods and systems for pulmonary delivery of recombinant human interferon alpha-2b
JP4767253B2 (ja) 2004-06-22 2011-09-07 ザイモジェネティクス, インコーポレイテッド トロンビン組成物

Also Published As

Publication number Publication date
WO2006009989A1 (en) 2006-01-26
DK1766003T3 (da) 2008-12-08
JP4767253B2 (ja) 2011-09-07
EP1766003B1 (de) 2008-08-20
IL179852A0 (en) 2007-05-15
CA2570478C (en) 2011-08-23
AU2005265251B2 (en) 2009-09-10
US7473543B2 (en) 2009-01-06
US7393674B2 (en) 2008-07-01
CA2570478A1 (en) 2006-01-26
ES2313383T3 (es) 2009-03-01
AU2009238369A1 (en) 2009-12-10
ES2395466T3 (es) 2013-02-12
AU2009238369B2 (en) 2012-05-24
DE602005009191D1 (de) 2008-10-02
US20060002918A1 (en) 2006-01-05
AU2005265251A1 (en) 2006-01-26
EP1766003A1 (de) 2007-03-28
JP2008503240A (ja) 2008-02-07
US20070104705A1 (en) 2007-05-10

Similar Documents

Publication Publication Date Title
DE602005009191D1 (de) Thrombinzusammensetzungen
NZ593190A (en) Factor viii formulations
WO2007056205A3 (en) Carboxyalkylcellulose esters for administration of poorly soluble pharmaceutically active agents
WO2008073448A3 (en) Pharmaceutical formulations and methods for making the same
ECSP045496A (es) "preparaciones acidas de insulina con estabilidad mejorada"
EA200970273A1 (ru) Применение 2-6-(3-аминопиперидин-1-ил)-3-метил-2,4-диоксо-3,4-дигидро-2н-пиримидин-1-илметил-4-фторбензонитрила
CY1108547T1 (el) Αναλογα σωματοστατινης
WO2007019232A3 (en) Immunoconjugate formulations
WO2008011559A3 (en) Synthetic lung surfactant and use thereof
WO2006081249A3 (en) Conjugates of biologically active proteins having a modified in vivo half-life
MY129417A (en) Zinc-free and low-zinc insulin preparations having improved stability
NZ596367A (en) Lyophilized therapeutic peptibody formulations
CY1113969T1 (el) Ανευ-αλβουμινης συνταγοποιησεις παραγοντα viii
ATE246202T1 (de) Gcsf konjugate
TN2009000362A1 (en) Weekly administration of dipeptidyl peptidase inhibitors
NZ601592A (en) Recombinant elastase proteins and methods of manufacturing and use thereof
WO2008060934A3 (en) Formulations of tetrahydropyridine antiplatelet agents for parenteral or oral administration
BRPI0513332A (pt) formulação de interferon peguilado estável
ECSP044967A (es) Formulaciones de deposito oftalmicas para administracion periocular o subconjuntival
YU46503A (sh) Farmaceutski oblik dronedarona za parenteralnu upotrebu
WO2005123135A8 (en) Stabilized compositions comprising a therapeutically active agent, citric acid or a conjugated base and chlorine dioxide
EA201070766A1 (ru) Стабильные при комнатной температуре лиофилизированные композиции натрийуретического пептида
TW200730538A (en) VIP fragments and methods of use
CA2528988A1 (en) Stable, aqueous solution of human erythropoietin, not containing serum albumin
IL155788A (en) A highly purified ifn – β active and mannitol-containing preparation, a method to make an improved stability of ifn – β active, and a method to enhance the stability of ifn – β in biologically active formulation.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1766003

Country of ref document: EP